All SUMO1 reagents are produced in house and quality controlled, including 3 SUMO1 Antibody, 45 SUMO1 Gene, 1 SUMO1 IPKit, 1 SUMO1 Protein, 2 SUMO1 qPCR. All SUMO1 reagents are ready to use.
Recombinant SUMO1 proteins are expressed by E. coli with fusion tags as N-His.
SUMO1antibodies are validated with different applications, which are ELISA, FCM, WB, IP.
SUMO1cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each SUMO1 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.